This category covers companies developing digital therapeutics (DTx) for Alzheimer's disease and cognitive impairment. These include FDA-cleared prescription digital therapeutics, gamified cognitive training programs, and software-based interventions targeting cognition, behavior, and functional outcomes.
| Company | Product | Status | Target |
|---|---|---|---|
| Pear Therapeutics | reSET-AD | FDA-cleared | Cognitive impairment |
| Akili Interactive | EndeavorRx | FDA-cleared | Pediatric attention |
| Click Therapeutics | CT-001 | Phase II | Cognitive impairment |
| Cogstate | BrainCheck | Commercial | Assessment |
Software-based exercises targeting memory, attention, and executive function. Evidence varies for transfer to real-world functioning.
Digital programs addressing neuropsychiatric symptoms including depression, anxiety, and agitation in AD.
DTx programs designed to maintain independence and daily functioning in MCI and early AD.